Article

George Van Antwerp Discusses PBM Engagement Models

George Van Antwerp, VP, Product Development, InVentiv Medical Management, suggests the pharmacy benefit manager (PBM) industry is truly exploring new ways of interacting with payers and providers.

George Van Antwerp, VP, Product Development, InVentiv Medical Management, suggests the pharmacy benefit manager (PBM) industry is exploring new ways of interacting with payers and providers. Companies like Prime Therapeutics are making value-based contracting deals that will require looking at data integration.

Mr Antwerp says such innovation will help PBMs better understand how to engage consumers in focusing on care and health management.

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe Now!
Related Videos
Dr Pankit Vachhani
Mansi Shah, MD
Dr John Mascarenhas
CK Wang, MD, COTA
Dr Pankit Vachhani
Screenshot of Ivo Abraham, PhD, RN, during a video interview
Merrill H. Stewart, MD
Dr John Mascarenhas
Carla Nester, MD, MSA, FASN, Stead Family Children's Hospital
Dr John Mascarenhas
Related Content
Hamlet Gasoyan, PhD
June 26th 2025

Improve Antiobesity Medication Adherence to Improve Results: Hamlet Gasoyan, PhD

Hayden E. Klein Hamlet Gasoyan, PhD
Conversations between the patient and provider should focus on the stakes of antiobesity treatment and continuation, says Hamlet Gasoyan, PhD, Cleveland Clinic.
Managed Care Cast
June 24th 2025

Addressing the Physical, Psychological Complexity of IBD Through Coordinated Care

Giuliana Grossi Skylar Jeremias Eva Szigethy, MD, PhD Benjamin Cohen, MD
Explore how the Specialty Medical Home model transforms care for patients with inflammatory bowel disease (IBD) by integrating mental health support and addressing stigma.
Colleen Kelley, MD, MPH
June 20th 2025

Accessibility Important After FDA Approves Lenacapavir for PrEP: Q&A With Colleen Kelley, MD, MPH

Julia Bonavitacola Colleen Kelley, MD, MPH
The approval of lenacapavir, a form of pre-exposure prophylaxis (PrEP), marks significant progress in preventing HIV, making it vital for the treatment to be available and accessible to those most vulnerable, explains Colleen Kelley, MD, MPH, Rollins School of Public Health at Emory University.
Logo for Managed Care Cast
June 19th 2025

Stuck in Prior Auth Purgatory: The Hidden Costs of Health Care Delays

Maggie L. Shaw Colin Banas, MD, MHA
Delays, denials, and endless paperwork—prior authorization isn’t just a headache for providers; it’s a barrier for patients who need timely care, explains Colin Banas, MD, MHA, chief medical officer with DrFirst.
Image credit: Yale School of Medicine
June 19th 2025

Lenacapavir Offers Promising Step Forward in HIV Prevention: Q&A With Onyema Ogbuagu, MBBCh, FACP, FIDSA

Julia Bonavitacola Onyema Ogbuagu, MBBCh, FACP, FIDSA
The approval of lenacapavir for use as pre-exposure prophylaxis is a significant step in reducing the incidence of HIV across the globe, including in areas where the PURPOSE trials were conducted.
Mansi Shah, MD
June 11th 2025

Stem Cell Transplant Remains Cost-Effective Option for MM: Mansi Shah, MD

Laura Joszt, MA Hayden E. Klein Mansi Shah, MD
Mansi Shah, MD, discusses the role of stem cell transplant in multiple myeloma (MM) and the logistical barriers to wider adoption of bispecific therapies.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo